Daily Brief Health Care: Dongkook Pharmaceutical Co Ltd, Wuxi Biologics, Elements Ventures Group, Actuate Therapeutics, City Therapeutics, Nexalin Technology and more

• There are three key investment highlights of Dongkook Pharmaceutical. First, the company has successfully expanded its cosmetics/health care business. Healthcare/cosmetics accounted for nearly 40% of total sales in 1H 2026. 
• Second, the company has highly consistent growth in sales and profits backed by solid sales of its core pharmaceutical/cosmetics brands including Madecassol, Insadol, Centellian24, and Madeca Cream.
• Third, it has cheap valuations. It is trading at P/E of 10.5x and P/B of 1.2x based on 2027 consensus earnings estimates.

• Geographically diversified capacity expansion is the crucial defense mechanism against geopolitical headwinds. WuXi Biologics is pivoting from its historical China-centric model to a global dual-sourcing strategy, relying on flagship sites like Dundalk, Ireland (48,000 liters of fed-batch and 6,000 liters of perfusion capacity) and the under-construction Singapore CRDMO hub (120,000 liters planned capacity) to retain Western clients.
• The regulatory clock is actively ticking despite legal reprieves. While the US District Court’s August 2026 preliminary injunction temporarily halted the DoD’s 1260H listing of sister company WuXi AppTec, the Biosecure Act (signed into law in December 2025) has structurally shifted Western client procurement behavior. Early-phase project win-rates are facing localized pressure, forcing WuXi to rely on late-stage “Win-the-Molecule” campaigns to sustain momentum.
• Capital allocation is prioritizing high-margin complexity and asset-light rationalization. The divestment of WuXi’s 51.1% stake in chromatography supplier BestChrom for 700 million RMB in late 2026 represents a pivot away from defensive supply-chain integration toward high-value modalities like ADCs via WuXi XDC. This capital recycling is reinforced by the parent-level 150 million share placement by WuXi Biologics Holdings in January 2026 to fund intensive CAPEX targets of 7.1 billion RMB in 2026 and 8.0 billion RMB in 2027.

• Elements Ventures Group Inc. is a development-stage consumer-wellness company focused on developing and commercializing FITLY, a mobile application for general health and wellness.
• The company is developing FITLY, a code-complete mobile application with five structured, multi-week wellness programs, designed for general fitness, nutrition, and healthy-lifestyle goals.
• The company reported net losses for 2024 and 2025, with an accumulated deficit, and its auditor expressed substantial doubt about its going concern ability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Marginal Clinical Utility in mPDAC: While elraglusib plus gemcitabine/nab-paclitaxel (GnP) demonstrated a statistically significant median overall survival improvement of 10.1 months versus 7.2 months in Phase 2, the control arm underperformed historic benchmarks. Crucially, elraglusib significantly exacerbates myelosuppression, with Grade 3+ neutropenia rising to 52.3% (versus 30.8% in the control), which complicates clinical adoption in an increasingly competitive front-line setting dominated by FOLFIRINOX and NALIRIFOX.
• Desperate Financing and Severe Dilution: Actuate is in a highly distressed financial position, ending Q1 2026 with just $8.1 million in cash. The S-1 filing on October 6, 2026, registering 50,000,000 shares at an assumed price of $0.819 per share, represents a highly dilutive capitulation. Drawing on their $100 million ATM facility at depressed prices (such as $2.68 per share earlier in the year) failed to secure the $60 million to $80 million required to launch a registrational Phase 3 trial.
• Pediatric Program as a Financial Arbitrage Play: The strategic pivot toward pediatric oncology (Ewing sarcoma and neuroblastoma) is driven by regulatory arbitrage rather than market size. Due to the ultra-orphan nature of Ewing sarcoma (200 to 250 new US cases annually), the commercial market is negligible. Instead, the strategy centers on obtaining a Rare Pediatric Disease Designation to secure a Priority Review Voucher (PRV), which can be sold to Big Pharma for $100 million to $200 million to non-dilutively fund the company’s broader pipeline.

• City Therapeutics is seeking an $856 million to $956 million valuation in an IPO, offering 9.72 million shares at $17–$19 each.
• The RNAi-focused biotech has advanced three programs toward the clinic, backed by experienced leadership and collaborations with Bausch + Lomb and Biogen.
• Despite strong industry validation, City remains an early-stage, pre-revenue company with limited clinical data and substantial development and funding risks.

• Nexalin Technology, Inc. is a medical device company developing innovative neurostimulation products to address the global mental health epidemic. The company’s bioelectronic devices treat anxiety, insomnia, and depression without drugs.
• The company developed Gen-1 CES devices and has Gen-2 SYNC and Gen-3 HALO devices in clinical trials, including an FDA-cleared trial for insomnia.
• The company reported significant net losses and negative cash flows from operations, with substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.